Ionis Pharmaceuticals, Inc.
http://www.ionispharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ionis Pharmaceuticals, Inc.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding
A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.
Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Akcea Therapeutics
- Regulus Therapeutics, Inc.
- Symphony GenIsis, Inc.
- Isis Pharmaceuticals, Inc.